Literature DB >> 33948364

Lycorine hydrochloride inhibits melanoma cell proliferation, migration and invasion via down-regulating p21Cip1/WAF1.

Shaomin Shi1,2,3,4, Chongyang Li3,4, Yanli Zhang1, Chaowei Deng3,4, Mengqin Tan3,4, Guangzhao Pan3,4, Juan Du1, Yacong Ji1, Qian Li1, Hanghua Liang3,4, Wei Liu1, Leiyang Guo1, Gaichao Zhao3,4, Yaling Liu1, Hongjuan Cui3,4.   

Abstract

Lycorine hydrochloride (LH) is an active ingredient sourced from the medicinal herb Lycoris radiata. Previous studies have suggested that LH exerts tumor suppression activity in several human cancers. However, the anti-cancer effect of LH in melanoma and the potential molecular mechanisms still need to be further studied. p21Cip1/WAF1, unlike its traditional cyclin-dependent kinase (CDK) inhibitor role, is believed to act as an oncogene under certain cellular conditions. In this research, an increased expression of p21Cip1/WAF1 was found in human melanoma tissues and positively related to the tumor invasion depth. High level of p21Cip1/WAF1 was found to correlate with bad outcomes of melanoma patients by Kaplan-Meier survival analysis. Functional experiments demonstrated that the proliferation, migration and invasion ability of A375 and MV3 melanoma cells was powerfully inhibited by LH through inducing S phase cell cycle arrest and regulating epithelial-mesenchymal transition (EMT). In NOD/SCID mice model, LH effectively inhibited the xenograft tumor growth and lung metastasis of A375 cells. Further research revealed that LH reduced p21Cip1/WAF1 protein by accelerating its ubiquitination. Importantly, the LH-induced suppression of cell proliferation and metastasis was rescued by p21Cip1/WAF1 overexpression, both in vitro an in vivo. Taken together, LH, which suppresses the proliferation and metastasis of melanoma cells via down-regulating p21Cip1/WAF1, is expected to be developed as an effective medicine for melanoma therapy. AJCR
Copyright © 2021.

Entities:  

Keywords:  Melanoma; cell proliferation; invasion; lycorine hydrochloride; migration; p21Cip1/WAF1

Year:  2021        PMID: 33948364      PMCID: PMC8085853     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  50 in total

1.  Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis.

Authors:  Z E Winters; N C Hunt; M J Bradburn; J A Royds; H Turley; A L Harris; C J Norbury
Journal:  Eur J Cancer       Date:  2001-12       Impact factor: 9.162

Review 2.  Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage.

Authors:  Ansar Karimian; Yasin Ahmadi; Bahman Yousefi
Journal:  DNA Repair (Amst)       Date:  2016-04-22

Review 3.  Advances in cancer therapy with plant based natural products.

Authors:  A K Mukherjee; S Basu; N Sarkar; A C Ghosh
Journal:  Curr Med Chem       Date:  2001-10       Impact factor: 4.530

Review 4.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

Review 5.  Melanoma.

Authors:  Conor H O'Neill; Charles R Scoggins
Journal:  J Surg Oncol       Date:  2019-06-27       Impact factor: 3.454

6.  A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition.

Authors:  Theresa Vincent; Etienne P A Neve; Jill R Johnson; Alexander Kukalev; Federico Rojo; Joan Albanell; Kristian Pietras; Ismo Virtanen; Lennart Philipson; Philip L Leopold; Ronald G Crystal; Antonio Garcia de Herreros; Aristidis Moustakas; Ralf F Pettersson; Jonas Fuxe
Journal:  Nat Cell Biol       Date:  2009-07-13       Impact factor: 28.824

7.  Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival.

Authors:  P Korkolopoulou; K Kouzelis; P Christodoulou; A Papanikolaou; E Thomas-Tsagli
Journal:  Acta Neuropathol       Date:  1998-06       Impact factor: 17.088

Review 8.  Tumor cell vasculogenic mimicry: from controversy to therapeutic promise.

Authors:  Richard E B Seftor; Angela R Hess; Elisabeth A Seftor; Dawn A Kirschmann; Katharine M Hardy; Naira V Margaryan; Mary J C Hendrix
Journal:  Am J Pathol       Date:  2012-08-31       Impact factor: 4.307

9.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.

Authors:  Soledad R Alonso; Pablo Ortiz; Marina Pollán; Beatriz Pérez-Gómez; Lydia Sánchez; Ma Jesús Acuña; Raquel Pajares; Francisco J Martínez-Tello; Carlos M Hortelano; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  CircAGFG1 promotes cervical cancer progression via miR-370-3p/RAF1 signaling.

Authors:  Fengqin Wu; Jingjing Zhou
Journal:  BMC Cancer       Date:  2019-11-08       Impact factor: 4.430

View more
  3 in total

Review 1.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

2.  Lycorine ameliorates isoproterenol-induced cardiac dysfunction mainly via inhibiting inflammation, fibrosis, oxidative stress and apoptosis.

Authors:  Ji Wu; Yang Fu; Ying-Xing Wu; Zu-Xiang Wu; Zhen-Hua Wang; Ping Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Lycorine inhibits angiogenesis by docking to PDGFRα.

Authors:  Fei Lv; XiaoQi Li; Ying Wang
Journal:  BMC Cancer       Date:  2022-08-10       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.